{"context":{"query":">>hgnc>>gwas","source_dataset":"hgnc","target_dataset":"gwas"},"stats":{"queried":1,"total":61,"mapped":1},"pagination":{"has_next":false},"schema":"id|disease_trait|mapped_gene|chr_id|p_value","mappings":[{"input":"HGNC:3688","source":"HGNC:3688|fibroblast growth factor receptor 1","targets":["GCST001106_1|Atopic dermatitis|CCDST|1|6.000000e-12","GCST001960_3|Eating disorders|CCDST|1|2.000000e-06","GCST002100_1|Atopic dermatitis|CCDST - LCE5A|1|9.000000e-11","GCST002737_1|Atopic dermatitis|CCDST - LCE5A|1|2.000000e-25","GCST003180_3|Atopic march|CCDST - LCE5A|1|9.000000e-11","GCST003184_30|Atopic dermatitis|CRCT1 - LCE3E|1|6.000000e-29","GCST003469_12|Response to cognitive-behavioural therapy in anxiety disorder|FGFR1 - LINC03042|8|4.000000e-06","GCST004166_49|Nonsyndromic cleft lip with cleft palate|FGFR1|8|4.000000e-08","GCST004521_142|Autism spectrum disorder or schizophrenia|FGFR1|8|4.000000e-09","GCST005038_56|Allergic disease (asthma, hay fever or eczema)|FLG, CCDST|1|7.000000e-21","GCST006218_24|Erosive tooth wear (severe vs non-severe)|LINC03042|8|6.000000e-06","GCST006218_25|Erosive tooth wear (severe vs non-severe)|LINC03042|8|6.000000e-06","GCST006218_68|Erosive tooth wear (severe vs non-severe)|LINC03042|8|8.000000e-09","GCST006218_69|Erosive tooth wear (severe vs non-severe)|LINC03042|8|2.000000e-08","GCST006218_70|Erosive tooth wear (severe vs non-severe)|LINC03042|8|2.000000e-08","GCST006218_71|Erosive tooth wear (severe vs non-severe)|LINC03042|8|2.000000e-08","GCST006226_13|Erosive tooth wear (severe vs none or mild)|LINC03042|8|5.000000e-06","GCST006226_14|Erosive tooth wear (severe vs none or mild)|LINC03042|8|5.000000e-06","GCST006661_183|Male-pattern baldness|PUDPP2 - RPTN|1|1.000000e-10","GCST006803_70|Schizophrenia|NSD3|8|6.000000e-10","GCST006911_7|Asthma (moderate or severe)|FLG, CCDST|1|1.000000e-08","GCST007045_31|PR interval|FGFR1 - LINC03042|8|5.000000e-10","GCST007563_33|Allergic disease (asthma, hay fever or eczema)|CCDST|1|3.000000e-11","GCST007564_35|Asthma or allergic disease (pleiotropy)|CCDST|1|5.000000e-12","GCST007798_8|Asthma|FLG, CCDST|1|1.000000e-30","GCST007994_17|Asthma (age of onset)|FLG, CCDST|1|8.000000e-27","GCST007995_26|Asthma (childhood onset)|FLG, CCDST|1|2.000000e-65","GCST008103_171|Bipolar disorder|LETM2|8|7.000000e-06","GCST008362_94|Birth weight|FGFR1 - LINC03042|8|8.000000e-11","GCST008916_100|Asthma|CCDST - LCE5A|1|2.000000e-08","GCST008916_2|Asthma|FLG, CCDST|1|5.000000e-27","GCST008916_36|Asthma|CCDST|1|1.000000e-25","GCST009600_6|Anorexia nervosa, attention-deficit/hyperactivity disorder, autism spectrum disorder, bipolar disorder, major depression, obsessive-compulsive disorder, schizophrenia, or Tourette syndrome (pleiotropy)|FGFR1|8|2.000000e-09","GCST009718_16|Eczema|CCDST|1|1.000000e-64","GCST009720_2|Asthma|CCDST|1|2.000000e-27","GCST009798_50|Asthma|CCDST|1|2.000000e-21","GCST009798_51|Asthma|FLG, CCDST|1|1.000000e-22","GCST010042_19|Asthma|FLG, CCDST|1|4.000000e-39","GCST010043_16|Asthma|FLG, CCDST|1|8.000000e-35","GCST010118_105|Type 2 diabetes|FGFR1 - LINC03042|8|4.000000e-08","GCST010244_265|Triglyceride levels|FGFR1 - LINC03042|8|4.000000e-09","GCST010321_68|PR interval|FGFR1 - LINC03042|8|3.000000e-19","GCST010796_2009|Electrocardiogram morphology (amplitude at temporal datapoints)|FGFR1|8|1.000000e-11","GCST010796_2010|Electrocardiogram morphology (amplitude at temporal datapoints)|FGFR1|8|2.000000e-08","GCST010796_2802|Electrocardiogram morphology (amplitude at temporal datapoints)|FGFR1|8|4.000000e-10","GCST010796_2803|Electrocardiogram morphology (amplitude at temporal datapoints)|FGFR1|8|6.000000e-09","GCST010796_67|Electrocardiogram morphology (amplitude at temporal datapoints)|FGFR1|8|2.000000e-08","GCST010796_68|Electrocardiogram morphology (amplitude at temporal datapoints)|FGFR1|8|3.000000e-08","GCST010796_69|Electrocardiogram morphology (amplitude at temporal datapoints)|FGFR1|8|3.000000e-09","GCST010796_70|Electrocardiogram morphology (amplitude at temporal datapoints)|FGFR1|8|2.000000e-08","GCST010796_71|Electrocardiogram morphology (amplitude at temporal datapoints)|FGFR1|8|3.000000e-09","GCST010796_72|Electrocardiogram morphology (amplitude at temporal datapoints)|FGFR1|8|2.000000e-09","GCST010796_73|Electrocardiogram morphology (amplitude at temporal datapoints)|FGFR1|8|3.000000e-09","GCST010796_74|Electrocardiogram morphology (amplitude at temporal datapoints)|FGFR1|8|9.000000e-10","GCST010796_75|Electrocardiogram morphology (amplitude at temporal datapoints)|FGFR1|8|2.000000e-10","GCST010984_49|Allergic disease (asthma, hay fever and/or eczema) (multivariate analysis)|FLG, CCDST|1|5.000000e-82","GCST010985_28|Allergic disease (asthma, hay fever and/or eczema) (age of onset)|FLG, CCDST|1|3.000000e-82","GCST010988_218|Adult body size|FGFR1 - LINC03042|8|7.000000e-09","GCST010989_14|Body size at age 10|FGFR1 - LINC03042|8|7.000000e-09","GCST90000047_63|Age at first sexual intercourse|FGFR1 - LINC03042|8|1.000000e-08","GCST90014325_55|Asthma|CCDST, FLG|1|7.000000e-23"]}]}